In mice bearing Ph+ ALL-674 or ALL-1222 cells, palbociclib plus BCL2 inhibitor (sabutoclax) significantly decreased the peripheral leukemia load[182]. This evidence concerns the gene BCL2 and acute lymphoblastic leukemia.